Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immuno...
Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
The approval of monoclonal antibodies against programmed death-ligand 1 (PD-L1) and programmed cell death protein (PD1) has changed the landscape of cancer treatment. To date, many immune checkpoint inhibitors (ICIs) have been approved by the FDA for the treatment of metastatic cancer as well as locally recurrent advanced cancer. However, immune-re...
Alternative Titles
Full title
Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_4370154b3816457fa9f776f941ca1895
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_4370154b3816457fa9f776f941ca1895
Other Identifiers
ISSN
2227-9059
E-ISSN
2227-9059
DOI
10.3390/biomedicines11061768
